Clinical trials: Overload
Transfusion-dependent Iron Overload
A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload
This study uses a single arm, multi-center, open-label trial design. The study will assess the efficacy and safety of 52 weeks of treatment with deferasirox (ICL670) in patients with evidence of transfusion induced iron overload.
- Trial name
- NCT00171821
- Testing
- Deferasirox
- Where
- 97 sites in Australia, Austria and 21 more
- Volunteers
- 1,784 people
- Sponsor
- Novartis Pharmaceuticals
Respiratory Failure, Volume Overload
Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis
Patients who are on mechanical ventilation in an intensive care unit often require diursis as part of their pre-extubation regimen. The drug of choice for diuresis has traditionally been furosemide.
- Conditions
- Respiratory Failure, Volume Overload, Hypernatremia
- Trial name
- SHUM (NCT01617798)
- Testing
- Supplemental metolazone diuresis
- Where
- United States
- Sponsor
- Oregon Health and Science University
Hemochromatosis, Iron Overload
MRI QSM Imaging for Iron Overload
The overall goal of this project is to develop and validate a novel technique for Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM) of the abdomen, for non-invasive assessment of liver iron…
- Trial name
- NCT04631718
- Testing
- Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM)
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of Wisconsin, Madison
Hypovolemia, Diuretic Toxicity
Diagnosis Accuracy of Abdominal Compression and Hemoconcentration to Detect Diuretic Induced Fluid Removal Intolerance.
Fluid overload increases morbidity and mortality of pediatrics patients in intensive care unit (ICU). It could be interesting to predict the decrease in stroke volume when diuretics are prescribed.
- Conditions
- Hypovolemia, Diuretic Toxicity, Fluid Overload
- Trial name
- NCT03145935
- Testing
- Abdominal compression (AC), blood sample
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Hopital Louis Pradel
Iron Overload
Retrospective Evaluation of Adult and Pediatric Transfusion-dependent Patients Treated With Deferasirox Therapy
Iron overload is a leading cause of morbidity and mortality in transfusion-dependent patients. Deferasirox is the most promising iron chelator agent in several clinical scenarios.
- Trial name
- NCT01874405
- Volunteers
- 80 people
- Sponsor
- University of Campania Luigi Vanvitelli
Iron Overload, Hemosiderosis
Non-invasive Quantification of Liver Iron With MRI
The purpose of this study is to validate magnetic resonance imaging as a biomarker of hepatic iron concentration (HIC). Excessive accumulation of iron in the body is highly toxic, specifically in the liver.
- Trial name
- NCT01516853
- Testing
- Non-contrast MRI
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Iron Overload, Thalassemia
Combination Iron Chelation Therapy
Patients with beta-thalassemia (Cooley's Anemia) continue to suffer from the transfusion-induced iron overload due to the inadequacies of current iron-chelation therapy.
- Trial name
- NCT00004982
- Testing
- Combination Iron Chelation Therapy
- Where
- United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Beta-Thalassemia, Hemosiderosis
A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
Because patients with beta-thalassemia are unable to actively eliminate iron from the body, toxic and eventually lethal levels of iron can accumulate as a result of repeated blood transfusions.
- Trial name
- NCT00171171
- Testing
- deferasirox
- Where
- 5 sites in Egypt, Lebanon and 3 more
- Volunteers
- 252 people
- Sponsor
- Novartis
Iron Overload, Transfusion-dependent Thalassemia
Endocrine Function During Deferasirox Therapy
A national survey on the prevalence and natural history of endocrine complications in thalassemia transfusion--dependent patients treated with deferasirox was designed, in order to assess a larger population during a longer…
- Conditions
- Iron Overload, Transfusion-dependent Thalassemia, Endocrine; Complications
- Trial name
- NCT04515680
- Where
- Italy
- Volunteers
- 426 people
- Sponsor
- University of Campania Luigi Vanvitelli
Transfusional Iron Overload
A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity
The purpose of this open-label, non-comparative, multi-center protocol was to further evaluate safety and to provide treatment with ICL670 to patients who had or were at risk of life threatening complications due to transfusional…
- Trial name
- NCT01044186
- Testing
- ICL670
- Where
- 18 sites in United States, Greece and 1 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Traumatic Brain Injury, Fluid Overload
Neutral Versus Liberal fLuId In Traumatic Brain Injury: a Randomised Controlled Trial
Feasibility and safety of targeting neutral vs liberal fluid balance in traumatic brain injured patients: a phase II randomized controlled trial
- Conditions
- Traumatic Brain Injury, Fluid Overload, Outcome, Fatal
- Trial name
- LIMIT (NCT05983549)
- Testing
- fluid balance
- Volunteers
- 80 people
- Sponsor
- Universita degli Studi di Genova
Genetic/Metabolic Liver Diseases
China Registry for Genetic / Metabolic Liver Diseases
CR-GMLD registry started on June 13, 2015 to collect cases of genetic/metabolic liver diseases from tertiary or secondary hospitals in mainland China.
- Trial name
- NCT03131427
- Testing
- Standard of care
- Where
- 12 sites in China
- Volunteers
- 20,000 people
- Sponsor
- Beijing Friendship Hospital
Heart Failure, Heart Failure (for Example, Fluid Overload)
Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling
The main objective of the study is to achieve a comprehensive phenotyping of patients with heart failure, combining detailed clinical characterization with in-depth molecular profiling.
- Trial name
- BIOCARDIUM-HF (NCT07158086)
- Where
- Switzerland
- Volunteers
- 500 people
- Sponsor
- University of Zurich
Coronavirus, SARS-CoV-2
Hemodynamic Characteristics of Patients With SARS-CoV-2
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a public health emergency of international concern.
- Conditions
- Coronavirus, SARS-CoV-2, COVID-19, Acute Respiratory Distress Syndrome
- Trial name
- PiCCOVID (NCT04337983)
- Testing
- Transpulmonary thermodilution, Echocardiography
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Bicetre Hospital
Thalassemia, Iron Overload
Long-term Clinical Study of CN128 in Thalassemia Patients
1. Primary objectives: To evaluate the safety and efficacy of long-term orally administration of CN128 in thalassaemia patients with blood transfusion dependent and aged 16 and above. 2.
- Trial name
- NCT04614779
- Testing
- CN128 Tablets
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hangzhou Zede Pharma-Tech Co., Ltd.
Cardiac Magnetic Resonance, Extracellular Volume Overload
Extracellular Volume Associated With New-Onset Atrial Fibrillation
Left ventricular fibrosis is strongly associated with atrial fibrillation (AF). However, the relationship between LV fibrosis and new-onset AF (NOAF) after ST-segment elevation myocardial infarction (STEMI) is currently unknown.
- Conditions
- Cardiac Magnetic Resonance, Extracellular Volume Overload, Myocardial Infarction, Atrial Fibrillation
- Trial name
- NCT06447857
- Testing
- Cardiac MRI
- Where
- China
- Volunteers
- 589 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Thalassemia, Iron Overload
Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients
The safety and efficacy of CN128 is studied in thalassaemia with sever liver iron overloaded patients.
- Trial name
- NCT05355766
- Testing
- CN128 Tablets
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Hangzhou Zede Pharma-Tech Co., Ltd.
Thalassemia Major
Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
This study aims to investigate the use of amlodipine, a drug that blocks the uptake of calcium into cells, in the prevention and treatment of iron overload in patients with thalassemia major.
- Trial name
- AnloThal (NCT01125254)
- Testing
- Amlodipine
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- University of Campinas, Brazil
Beta-thalassemia Major, Iron Overload
Therapeutic Effects of Silymarin in Patients With B-thalassemia Major
Silymarin, a flavonolignan complex isolated from Silybum marianum, has a strong antioxidant, hepatoprotective and iron chelating activities.
- Trial name
- NCT00999349
- Testing
- Silymarin (LEGALON)
- Where
- Iran
- Volunteers
- 140 people
- Sponsor
- Isfahan University of Medical Sciences
Iron Overload, Oxidative Stress
Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children
The purpose of study is to evaluate and compare the effect of iron supplementation when given as iron tablet or fortified biscuit or combined with zinc in the form of tablet on morbidity and iron toxicity markers among children…
- Trial name
- NCT00980421
- Testing
- Iron Supplementation
- Where
- India
- Volunteers
- 240 people
- Sponsor
- Annamalai University